- Home
- BIRD vs ACET Comparison
BIRD vs ACET Comparison
Compare BIRD & ACET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIRD
- ACET
- Stock Information
- Founded
- BIRD 2015
- ACET 1947
- Country
- BIRD United States
- ACET United States
- Employees
- BIRD N/A
- ACET N/A
- Industry
- BIRD Apparel
- ACET Biotechnology: Pharmaceutical Preparations
- Sector
- BIRD Consumer Discretionary
- ACET Health Care
- Exchange
- BIRD Nasdaq
- ACET Nasdaq
- Market Cap
- BIRD 87.0M
- ACET 93.1M
- IPO Year
- BIRD 2021
- ACET N/A
- Fundamental
- Price
- BIRD $7.71
- ACET $0.96
- Analyst Decision
- BIRD Hold
- ACET Strong Buy
- Analyst Count
- BIRD 4
- ACET 4
- Target Price
- BIRD $21.50
- ACET $5.67
- AVG Volume (30 Days)
- BIRD 59.8K
- ACET 790.0K
- Earning Date
- BIRD 11-06-2024
- ACET 11-06-2024
- Dividend Yield
- BIRD N/A
- ACET N/A
- EPS Growth
- BIRD N/A
- ACET N/A
- EPS
- BIRD N/A
- ACET N/A
- Revenue
- BIRD $205,895,000.00
- ACET N/A
- Revenue This Year
- BIRD N/A
- ACET N/A
- Revenue Next Year
- BIRD N/A
- ACET N/A
- P/E Ratio
- BIRD N/A
- ACET N/A
- Revenue Growth
- BIRD N/A
- ACET N/A
- 52 Week Low
- BIRD $7.25
- ACET $0.89
- 52 Week High
- BIRD $29.00
- ACET $3.77
- Technical
- Relative Strength Index (RSI)
- BIRD 40.65
- ACET 37.41
- Support Level
- BIRD $7.58
- ACET $0.91
- Resistance Level
- BIRD $8.28
- ACET $0.98
- Average True Range (ATR)
- BIRD 0.47
- ACET 0.08
- MACD
- BIRD 0.07
- ACET 0.00
- Stochastic Oscillator
- BIRD 17.14
- ACET 16.29
About BIRD Allbirds Inc.
Allbirds Inc is a lifestyle brand that innovates with naturally derived materials to make footwear and apparel products in a better way, while treading lighter on the planet. Its primary source of revenue is from sales of shoes and apparel products. The majority of the revenue is derived from United States.
About ACET Adicet Bio Inc.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its lead product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its lead preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.